How rituximab changes immune cells in membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have membranous nephropathy and test positive for anti-PLA2R1 antibodies.
- You have active nephrotic syndrome (high protein in urine and low blood albumin levels).
- You are going to receive rituximab as part of your standard care.
- Your kidney function is reasonably good (eGFR above 30).
- You have not taken immunosuppressive drugs in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
This study looks at blood and tissue samples from people with membranous nephropathy, a kidney disease, to find biological markers that predict whether rituximab, a treatment, will work. The goal is to understand why some patients do not respond, which could lead to better personalized treatment.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.